ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Order Full text via Infotrieve
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weynants, P
Right arrow Articles by Symann, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weynants, P
Right arrow Articles by Symann, M
Eur Respir J 1990; 3: 699-714
Copyright © ERS Journals Ltd 1990


Original Articles

Biology of small cell lung cancer: an overview

P Weynants, Y Humblet, JL Canon, and M Symann

Despite disappointing results in the treatment of small cell lung cancer (SCLC), major progress in our understanding of SCLC biology has occurred in the past decade. Advances in the technique for culturing SCLC tumours in vitro have greatly facilitated the study of the biological properties of this tumour. The major progress in our understanding of SCLC includes: 1) the availability of nonspecific biological tumour markers such as neuron-specific enolase (NSE), the BB isoenzyme of creatine phosphokinase (CPKBB), bombesin/gastrin releasing peptide (GRP) and chromogranin A; 2) the generation of monoclonal antibodies raised against the neural and epithelial features of SCLC tumours; 3) the identification of several autocrine growth factors such as bombesin/GRP, insulin-like growth factor (IGF), transferrin and physalaemin; 4) the close study of cytogenetic abnormalities leading to the discovery of a unique chromosomal deletion of the short arm of chromosome 3 (del 3p 14-21), and to changes in oncogenic expression, e.g. c-myc, L-myc and N-myc, accounting for known biological and treatment results. These data suggest that all lung cancers arise from a common stem cell of endodermal origin. The information derived from these biological studies represents the most promising avenue towards new treatment strategies in SCLC.


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
Y.-P. Sher, J.-Y. Shih, P.-C. Yang, S. R. Roffler, Y.-W. Chu, C.-W. Wu, C.-L. Yu, and K. Peck
Prognosis of Non-Small Cell Lung Cancer Patients by Detecting Circulating Cancer Cells in the Peripheral Blood with Multiple Marker Genes
Clin. Cancer Res., January 1, 2005; 11(1): 173 - 179.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
J. Kulpa, E. Wojcik, M. Reinfuss, and L. Kolodziejski
Carcinoembryonic Antigen, Squamous Cell Carcinoma Antigen, CYFRA 21-1, and Neuron-specific Enolase in Squamous Cell Lung Cancer Patients
Clin. Chem., November 1, 2002; 48(11): 1931 - 1937.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
E. Sher, P. Cesare, A. Codignola, F. Clementi, P. Tarroni, A. Pollo, V. Magnelli, and E. Carbone
Activation of delta -Opioid Receptors Inhibits Neuronal-Like Calcium Channels and Distal Steps of Ca2+-Dependent Secretion in Human Small-Cell Lung Carcinoma Cells
J. Neurosci., June 1, 1996; 16(11): 3672 - 3684.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the European Respiratory Society.